

## AMENDMENTS TO THE CLAIMS

Claim 1. (canceled)

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (canceled)

Claim 5. (canceled)

Claim 6 (canceled)

Claim 7 (canceled).

Claim 8. (previously presented) A two-pulse release pharmaceutical composition comprising:  
1) a first component comprising a therapeutically effective amount of rivastigmine wherein 70 to 95% of said rivastigmine is released in water within 3 to 4 hours; and 2) a second component comprising a core containing a therapeutically effective amount of rivastigmine and a coating wherein the coating comprises an outer film and an inner film, the inner film being in the form of a membrane which is semi-permeable to water or body fluids, and wherein rivastigmine is released 6 to 12 hours after ingestion.

Claim 9 (new) A pharmaceutical composition according to claim 8 wherein said outer film is permeable to water or body fluids.

Claim 10 (new) A pharmaceutical composition according to claim 8 wherein said coating has a thickness of 50 to 800 micrometers.

Claim 11 (new) A pharmaceutical composition according to claim 8 wherein said core releases an effective dose of said rivastigmine 6 to 12 hours after ingestion